| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| O M Littrell, J L Fuqua, A D Richardson, J Turchan-Cholewo, E R Hascup, P Huettl, F Pomerleau, L H Bradley, D M Gash, G A Gerhard. A synthetic five amino acid propeptide increases dopamine neuron differentiation and neurochemical function. Neuropeptides. vol 47. issue 1. 2013-07-16. PMID:22981157. |
a major consequence of parkinson's disease (pd) involves the loss of dopaminergic neurons in the substantia nigra (sn) and a subsequent loss of dopamine (da) in the striatum. |
2013-07-16 |
2023-08-12 |
rat |
| Dominic J Hare, Paul A Adlard, Philip A Doble, David I Finkelstei. Metallobiology of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. Metallomics : integrated biometal science. vol 5. issue 2. 2013-07-12. PMID:23322189. |
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (mptp) is a potent toxin used to selectively destroy dopaminergic neurons in the substantia nigra and induce parkinsonism. |
2013-07-12 |
2023-08-12 |
human |
| Adriane Gröger, Benjamin Bender, Isabel Wurster, Grzegorz Lukasz Chadzynski, Uwe Klose, Daniela Ber. Differentiation between idiopathic and atypical parkinsonian syndromes using three-dimensional magnetic resonance spectroscopic imaging. Journal of neurology, neurosurgery, and psychiatry. vol 84. issue 6. 2013-07-12. PMID:23334525. |
degeneration of dopaminergic neurons in the substantia nigra (sn) pars compacta is the primary cause of idiopathic parkinson's disease (ipd). |
2013-07-12 |
2023-08-12 |
Not clear |
| Bubblepreet K Randhawa, Becky G Farley, Lara A Boy. Repetitive transcranial magnetic stimulation improves handwriting in Parkinson's disease. Parkinson's disease. vol 2013. 2013-07-10. PMID:23841021. |
parkinson disease (pd) is characterized by hypometric movements resulting from loss of dopaminergic neurons in the substantia nigra. |
2013-07-10 |
2023-08-12 |
Not clear |
| Susan Searles Nielsen, Theo K Bammler, Lisa G Gallagher, Federico M Farin, Wt Longstreth, Gary M Franklin, Phillip D Swanson, Harvey Checkowa. Genotype and age at Parkinson disease diagnosis. International journal of molecular epidemiology and genetics. vol 4. issue 1. 2013-07-04. PMID:23565323. |
parkinson disease (pd) is a degenerative movement disorder that results from the destruction of dopaminergic neurons in the midbrain substantia nigra. |
2013-07-04 |
2023-08-12 |
Not clear |
| Adeline Burguière, Dimitri De Bundel, Emmanuel Valjent, Jonathan Roger, Ilse Smolders, Laurent Fagni, Julie Perro. Combination of group I mGlu receptors antagonist with dopaminergic agonists strengthens the synaptic transmission at corticostriatal synapses in culture. Neuropharmacology. vol 66. 2013-07-02. PMID:22465815. |
dendrites of striatal medium spiny neurons (msns) receive dopaminergic inputs from the substantia nigra and glutamatergic cortical afferents. |
2013-07-02 |
2023-08-12 |
Not clear |
| S Ares-Santos, N Granado, R Moratall. The role of dopamine receptors in the neurotoxicity of methamphetamine. Journal of internal medicine. vol 273. issue 5. 2013-07-02. PMID:23600399. |
genetic inactivation of dopamine d1 or d2 receptors protects against the loss of dopaminergic fibres in the striatum and loss of dopaminergic neurons in the substantia nigra. |
2013-07-02 |
2023-08-12 |
mouse |
| Johannes Meiser, Daniel Weindl, Karsten Hille. Complexity of dopamine metabolism. Cell communication and signaling : CCS. vol 11. issue 1. 2013-06-28. PMID:23683503. |
: parkinson's disease (pd) coincides with a dramatic loss of dopaminergic neurons within the substantia nigra. |
2013-06-28 |
2023-08-12 |
Not clear |
| Dennis W Dickso. Parkinson's disease and parkinsonism: neuropathology. Cold Spring Harbor perspectives in medicine. vol 2. issue 8. 2013-06-26. PMID:22908195. |
parkinsonism, the clinical term for a disorder with prominent bradykinesia and variable associated extrapyramidal signs and symptoms, is accompanied by degeneration of the nigrostriatal dopaminergic system, with neuronal loss and reactive gliosis in the substantia nigra found at autopsy. |
2013-06-26 |
2023-08-12 |
Not clear |
| Y Nakata, T Yasuda, H Mochizuk. Recent progress in gene therapy for Parkinson's disease. Current molecular medicine. vol 12. issue 10. 2013-06-20. PMID:22834832. |
a neuropathological hallmark of pd is a prominent loss of dopaminergic neurons in the substantia nigra projecting into the caudate and putamen. |
2013-06-20 |
2023-08-12 |
Not clear |
| Jeung Hee An, Byung-Keun Oh, Jeong Woo Cho. Detection of tyrosine hydroxylase in dopaminergic neuron cell using gold nanoparticles-based barcode DNA. Journal of biomedical nanotechnology. vol 9. issue 4. 2013-06-17. PMID:23621023. |
tyrosine hydroxylase, the rate-limiting enzyme of catecholamine biosysthesis, is predominantly expressed in several cell groups within the brain, including the dopaminergic neurons of the substantia nigra and ventral tegmental area. |
2013-06-17 |
2023-08-12 |
Not clear |
| Annadurai Anandhan, Musthafa Mohamed Essa, Thamilarasan Manivasaga. Therapeutic attenuation of neuroinflammation and apoptosis by black tea theaflavin in chronic MPTP/probenecid model of Parkinson's disease. Neurotoxicity research. vol 23. issue 2. 2013-06-14. PMID:22669749. |
neuroinflammation and apoptosis in the dopaminergic neurons of substantia nigra play an important role in the pathogenesis of experimental and clinical parkinson's disease (pd). |
2013-06-14 |
2023-08-12 |
mouse |
| Alison I Bernstein, Karen L O'Malle. MPP+-induces PUMA- and p53-dependent, but ATF3-independent cell death. Toxicology letters. vol 219. issue 2. 2013-06-14. PMID:23500530. |
parkinson's disease (pd) is characterized by the progressive loss of dopaminergic neurons in the substantia nigra (sn) and depletion of striatal dopamine (da), leading to a range of motor symptoms, including resting tremor, rigidity, bradykinesia and postural abnormalities. |
2013-06-14 |
2023-08-12 |
mouse |
| Francisco Pan-Montojo, Richard H W Fun. Implications of Parkinson's disease pathophysiology for the development of cell replacement strategies and drug discovery in neurodegenerative diseases. CNS & neurological disorders drug targets. vol 11. issue 7. 2013-06-13. PMID:23131153. |
parkinson's disease (pd) is a progressive neurodegenerative disorder traditionally characterized by the loss of dopaminergic neurons in the substantia nigra (sn) at the midbrain. |
2013-06-13 |
2023-08-12 |
Not clear |
| Peizhou Jiang, Ming Gan, Shu-Hui C Ye. Dopamine prevents lipid peroxidation-induced accumulation of toxic α-synuclein oligomers by preserving autophagy-lysosomal function. Frontiers in cellular neuroscience. vol 7. 2013-06-12. PMID:23754979. |
the formation of lewy bodies containing α-synuclein (α-syn), prominent loss of dopaminergic neurons and dopamine (da) deficiency in substantia nigra and striatum are histopathological and biochemical hallmarks of parkinson's disease (pd). |
2013-06-12 |
2023-08-12 |
human |
| Sarah Jesse, Jan Kassubek, Hans-Peter Müller, Albert C Ludolph, Alexander Unrat. Signal alterations of the basal ganglia in the differential diagnosis of Parkinson's disease: a retrospective case-controlled MRI data bank analysis. BMC neurology. vol 12. 2013-06-06. PMID:23273141. |
based upon the acquainted loss of dopaminergic neurons in the substantia nigra in parkinson's disease (pd), we hypothesised changes in magnetic resonance imaging signal intensities of the basal ganglia to be useful as an additional technical tool in the diagnostic work-up. |
2013-06-06 |
2023-08-12 |
Not clear |
| Wei Zhang, Luigi Zecca, Belinda Wilson, Hong-Wei Ren, Yong-Jun Wang, Xiao-Min Wang, Jau-Shyong Hon. Human neuromelanin: an endogenous microglial activator for dopaminergic neuron death. Frontiers in bioscience (Elite edition). vol 5. 2013-06-05. PMID:23276965. |
substantial evidence indicates that neuroinflammation caused by microglial activation in substantia nigra is critical in the pathogenesis of dopaminergic neurodegeneration in parkinson's disease (pd). |
2013-06-05 |
2023-08-12 |
human |
| Wei Zhang, Luigi Zecca, Belinda Wilson, Hong-Wei Ren, Yong-Jun Wang, Xiao-Min Wang, Jau-Shyong Hon. Human neuromelanin: an endogenous microglial activator for dopaminergic neuron death. Frontiers in bioscience (Elite edition). vol 5. 2013-06-05. PMID:23276965. |
here, potential role and mechanism of neuromelanin (nm), a major endogenous component in dopaminergic neurons of substantia nigra, on microglial activation and associated dopaminergic neurotoxicity were investigated. |
2013-06-05 |
2023-08-12 |
human |
| Joyce P M van der Vegt, Oliver J Hulme, Simone Zittel, Kristoffer H Madsen, Michael M Weiss, Carsten Buhmann, Bastiaan R Bloem, Alexander Münchau, Hartwig R Siebne. Attenuated neural response to gamble outcomes in drug-naive patients with Parkinson's disease. Brain : a journal of neurology. vol 136. issue Pt 4. 2013-05-30. PMID:23442226. |
parkinson's disease results from the degeneration of dopaminergic neurons in the substantia nigra, manifesting as a spectrum of motor, cognitive and affective deficits. |
2013-05-30 |
2023-08-12 |
human |
| Kangyong Liu, Nan Shi, Yinyi Sun, Ting Zhang, Xiaojiang Su. Therapeutic effects of rapamycin on MPTP-induced Parkinsonism in mice. Neurochemical research. vol 38. issue 1. 2013-05-29. PMID:23117422. |
immunohistochemistry using antibodies against th indicated that the number of dopaminergic neurons in the substantia nigra following mptp treatment was significantly higher in rapamycin-treated mice compared with saline-treated controls (p < 0.01). |
2013-05-29 |
2023-08-12 |
mouse |